Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


mtm laboratories launches CINtec Cytology kit in Europe with extended clinical claims for ...


mtm laboratories launches CINtec Cytology kit in Europe with extended clinical claims for cervical cancer diagnosis

Pivotal trial data shows comparable sensitivity and superior specificity in detecting High Grade Disease in equivocal/low grade Pap Test results vs. HPV testing

Heidelberg, Germany; September 17, 2008. mtm laboratories, a fully integrated cancer diagnostics company with proprietary products marketed globally, today announced the launch of the CE-labeled CINtec® Cytology kit with extended claims for the diagnosis of cervical cancer in Europe. The clinical claims are derived from the outcome of a recent pan-European pivotal study involving pathologists and cytotechnologists from France, England, Spain, Italy and Germany.

The multi-center trial was conducted to determine the sensitivity and specificity for the detection of underlying high grade disease for women with ASC-US (equivocal) or Low Grade (mild abnormality) cytology results to High Risk HPV (HR-HPV) testing. The overall sensitivity for the detection of CIN2 and higher grade disease exceeded 92%, which was essentially the same as that of HR-HPV testing. However, the specificity of CINtec Cytology was 67-100% higher than that of HR-HPV testing.

Ruediger Ridder, CSO of mtm laboratories, commented:

“Equivocal or mild results such as those examined in the study are clinically relevant since a portion of these actually harbour high grade disease, the immediate pre-cursor to Cervical Cancer, and as such cannot be ignored. However, it is costly and inefficient to treat or manage all of the cases based on the initial cytology finding, which is why a more accurate biomarker-based test such as CINtec® Cytology is needed to pinpoint those cases where there is high grade disease.”

Bob Silverman, CEO of mtm laboratories, commented:

'Approximately 6-8% of Pap Test results will be equivocal or mildly abnormal. While the majority of these diagnoses are benign, 10-15% of these cases will harbour high grade disease creating a clinical dilemma for clinicians. The results of this trial demonstrate that CINtec Cytology can more accurately identify those women with high grade disease than managing these cases with HR-HPV testing. This is a major advance in cervical cancer screening, and for the women participating in screening programs.'

The CINtec ® Cytology Kit is an immuno-cytochemistry assay for the qualitative detection of the p16INK4a antigen on cervical cytology preparations. It is intended to be used as an aid in the identification of women with underlying high-grade cervical intraepithelial lesions in the sub-group of patients with a Pap cytology result of ASC-US (atypical squamous cells of undetermined significance) or LSIL (low grade intraepithelial lesion).

mtm's CE-labeled CINtec® Cytology kit with extended claims will be marketed solely outside of the U.S.

Disclaimer: This IVD product and the use presented herein has not been cleared or approved by authorities in the United States including the United States Food and Drug Administration.


mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with the headquarter in Heidelberg, Germany and subsidiaries in the United States, France, Italy, Spain and Japan. Further information can be found at: www.mtmlabs.com.

Further Information:

Bob Silverman
CEO
mtm laboratories AG
t: +1 508 366 8334
e: contact@mtmlabs.com


Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com

Notes for editors:

The CINtec® family of diagnostic products
mtm's family of products is based on mtm's proprietary E6H4TM antibody clone which was specifically developed for immunochemistry applications in cervical histology and cytology specimens. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. The over-expression of this biomarker is directly correlated to the oncogenic activity of High Risk Human Papilloma Virus (HR-HPV) that marks the generation of cervical cancer. These biomarker-based diagnostic assays hold the promise to bring high levels of sensitivity and specificity towards the detection of high grade cervical disease in adjunctive uses with conventional technologies.

The CINtec® immunoassays are validated to provide a sensitive and specific method for the detection of p16INK4a in cervical tissues. The currently marketed CINtec® In-vitro Diagnostics (IVDs) have been developed for application on:

cervical biopsies (CINtec® Histology) and cervical cytology preparations such as smears and liquid based cytology samples (CINtec® Cytology) CINtec® products are available on a global basis through mtm's direct operations and distributors.


Publisher Contact Information:

mtm laboratories AG
+1 508 366 8334
contact@mtmlabs.com

Company profile of mtm laboratories AG
Past press releases of mtm laboratories AG.

Data


26,008
Tech investments
From our Online Data Service
16,823
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Aug 19€7.0MAgriculture related
Aug 19€9.0MInternet commerce
Aug 19€10.0ME-Commerce
Aug 19€63.0MBusiness applications
Aug 16€16.0ME-Commerce
Aug 16€6.0MBusiness applications
Aug 15€20.0MGames

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.